Compound: Tucatinib
SMILES: O1C(=NC(C1)(C)C)Nc2cc3c(ncnc3cc2)Nc4cc(c(Oc5cc6ncnn6cc5)cc4)C
InChIKey: SDEAXTCZPQIFQM-UHFFFAOYSA-N
Synonyms: Tucatinib, Irbinitinib, 937263-43-9, Tukysa, ONT-380, N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine, 234248D0HH, MK-7119, DTXSID601027958, 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-, 4,6-QuinazolinediaMine, N6-(4,5-dihydro-4,4-diMethyl-2-oxazolyl)-N4-[3-Methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-, N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine, N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-A)pyridin-7-Yloxy)phenyl)-4,6-quinazolinediamine, N6-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-N4-(3-methyl-4-{[1,2,4]triazolo[1,5-a]pyridin-7-yloxy}phenyl)quinazoline-4,6-diamine, tucatinibum, N6-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine, N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine, N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)-4,6-quinazolinediamine, RefChem:58754, DTXCID801513525, 6-DIAMINE, N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, Irbinitinib; ARRY-380; ONT-380, Tukysa (TN), Tucatinib [INN], 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine, Arry 380, UNII-234248D0HH, ONT 380, C26H24N8O2, MFCD22380467, Tucatinib; Irbinitinib, ONT-380;Tucatinib, TUCATINIB [MI], Tucatinib (USAN/INN), Tucatinib [USAN:INN], TUCATINIB [USAN], Irbinitinib(ARRY-380), Irbinitinib; ARRY-380, TUCATINIB [WHO-DD], GTPL9922, orb1305592, SCHEMBL1193050, TUCATINIB [ORANGE BOOK], CHEMBL3989868, SCHEMBL29351516, SCHEMBL29351934, SCHEMBL29475609, SCHEMBL29653672, SDEAXTCZPQIFQM-UHFFFAOYSA-N, BDBM471617, GLXC-08059, HMS5086M09, EX-A1031, Tucatinib (Irbinitinib, ONT-380), EBC-27208, NSC764581, NSC799335, s8362, ARRY-380 (ONT-380), Tucatinib (Irbinitinib,ARRY-380)?, AKOS026750449, CCG-264747, CS-3906, DB11652, NSC-764581, NSC-799335, SB17126, US10822334, Compound ONT380, NCGC00482879-02, AC-33037, AS-56109, BP-40974, BT177688, HY-16069, Example 11 [WO2007059257A2], DB-130430, NS00072928, D11141, EN300-24438049, BRD-K26026438-001-01-0, Q25100690, ARRY-380; 4,6-Quinazolinediamine, N6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-; N6-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4,6-quinazolinediamine;, N6-(4,4-dimethyl-5H-oxazol-2-yl)-N4-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
Theoretical properties:
molecular_formula: C26H24N8O2
molecular_weight: 480.5 g/mol
exact_mass: 480.20222204 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 6
heavy_atom_count: 36
topological_polar_surface_area: 111 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
chembl: TUCATINIB is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics).
Common side effects include diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage), vomiting, stomatitis (inflammation of the mouth and lips), decreased appetite, abdominal pain, headache, anemia and rash. Tucatinib may cause harm to a developing fetus or baby.
Tucatinib was approved for medical use in the United States in April 2020, in Australia in August 2020, and in the European Union in February 2021.